Cellectis S.A. (NASDAQ:CLLS) Short Interest Down 6.5% in November

Cellectis S.A. (NASDAQ:CLLS) saw a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 131,400 shares, a decline of 6.5% from the November 15th total of 140,500 shares. Based on an average trading volume of 56,100 shares, the short-interest ratio is currently 2.3 days.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Barclays decreased their price target on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. StockNews.com initiated coverage on shares of Cellectis in a report on Sunday. They set a “sell” rating on the stock.

Institutional Trading of Cellectis

Hedge funds have recently made changes to their positions in the business. Long Focus Capital Management LLC raised its holdings in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after buying an additional 130,000 shares during the period. First Affirmative Financial Network bought a new stake in shares of Cellectis during the third quarter worth $45,000. XTX Topco Ltd purchased a new stake in shares of Cellectis during the second quarter valued at $29,000. Finally, Principal Financial Group Inc. increased its stake in Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after buying an additional 12,467 shares during the period. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

Cellectis Stock Performance

Shares of NASDAQ:CLLS traded down $0.03 during trading on Monday, hitting $1.73. The company’s stock had a trading volume of 55,402 shares, compared to its average volume of 51,203. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The firm has a market cap of $96.16 million, a price-to-earnings ratio of -1.33 and a beta of 3.09. The company has a 50-day moving average of $1.92 and a 200-day moving average of $2.09. Cellectis has a 12 month low of $1.70 and a 12 month high of $3.77.

Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The firm had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. During the same quarter in the previous year, the business posted ($0.31) EPS. On average, sell-side analysts expect that Cellectis will post -0.46 earnings per share for the current year.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.